Your browser doesn't support javascript.
loading
Early Allogeneic Transplantation Favorably Influences the Outcome of Pediatric Acute Myeloid Leukemia-A Retrospective Study in a Single Center Over 2 Decades.
Lo, Tzu-Ya; Wang, Yi-Lun; Jaing, Tang-Her; Chang, Tsung-Yen; Wen, Yu-Chuan; Chiu, Chia-Chi; Hsiao, Yi-Wen; Chen, Shih-Hsiang.
Affiliation
  • Lo TY; Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan. Electronic address: lydia.88811@gmail.com.
  • Wang YL; Divisions of Hematology and Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
  • Jaing TH; Divisions of Hematology and Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
  • Chang TY; Divisions of Hematology and Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
  • Wen YC; Department of Nursing, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Chiu CC; Department of Nursing, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Hsiao YW; Department of Nursing, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Chen SH; Divisions of Hematology and Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
Transplant Proc ; 56(1): 201-210, 2024.
Article in En | MEDLINE | ID: mdl-38245493
ABSTRACT

BACKGROUND:

Transplantation advancements offer the potential for improving the prognosis of patients with acute myeloid leukemia (AML). Controversies surrounding indications and timing persist. We focused on identifying prognostic factors and exploring the advantages of early transplantation. PATIENTS AND

METHODS:

We studied 102 pediatric patients with AML (February 1999-August 2022), using Cox regression to analyze survival and hematopoietic cell transplantation (HCT) outcomes and Kaplan-Meier curves to assess HCT timing's impact on prognosis.

RESULTS:

"Treatment in First Complete Remission [CR1] Chemotherapy" showed increased risk in multivariate and univariate Cox regression analyses, whereas "HCT during the study period" displayed divergent outcomes. Focusing on transplanted patients, "Treatment in CR1 Chemotherapy" still correlated with higher mortality risk. These findings emphasize the pivotal role of the treatment strategy adopted in CR1 on overall survival rather than HCT alone. Donor cytomegalovirus (CMV) positivity is also related to reduced mortality risk. Kaplan-Meier analysis supported superior 5-year survival rates with "HCT" compared with "chemotherapy" in CR1. In the 3-arm analysis, "HCT in CR1" demonstrated better 5-year overall survival (OS) and 5-year disease-free survival (DFS) compared with "Never HCT," whereas "HCT in CR2" had the least favorable prognosis (5-year OS 79.2% vs 57.1% vs 50%, P = .056; 5-year DFS 73.6% vs 55.2% vs 0%, P = .000).

CONCLUSION:

Our study highlights the benefits of transplantation during CR1 on prognosis. However, when contemplating CR1 transplantation recommendations, evaluation of various factors, such as the patient's clinical state, relapse risk, transplant-related mortality, CMV status, and other pertinent considerations, is vital. Comprehensive case discussions with patients and families are demanded in optimizing treatment.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Cytomegalovirus Infections / Hematopoietic Stem Cell Transplantation Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Child / Humans Language: En Journal: Transplant Proc Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Cytomegalovirus Infections / Hematopoietic Stem Cell Transplantation Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Child / Humans Language: En Journal: Transplant Proc Year: 2024 Document type: Article
...